The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EYEN | -41.3% | -99.12% | -61.15% | -99% |
| S&P | +14.77% | +87.2% | +13.35% | +144% |
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
No news articles found for Hyperion DeFi.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $302.51K | 18515.8% |
| Gross Profit | -$75.59K | 90.1% |
| Gross Margin | -413.85% | 6224.6% |
| Market Cap | $54.55M | 22.3% |
| Market Cap / Employee | $3.90M | 0.0% |
| Employees | 14 | -75.4% |
| Net Income | $6.63M | 184.0% |
| EBITDA | -$2,816.66K | 60.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.22M | 14.4% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.00M | 168.6% |
| Short Term Debt | $494.66K | -95.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.31% | 82.9% |
| Return On Invested Capital | -6.67% | 116.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,799.86K | 52.9% |
| Operating Free Cash Flow | -$2,822.82K | 52.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.34 | 0.32 | -3.02 | 1.25 | -89.62% |
| Price to Sales | 232.23 | 35.90 | 821.96 | 803.20 | -28.85% |
| Price to Tangible Book Value | -419.73 | -0.49 | -3.02 | 1.25 | -100.08% |
| Enterprise Value to EBITDA | -2.80 | -3.26 | -4.53 | -98.57 | 1561.29% |
| Return on Equity | -914.7% | -388.0% | -228.7% | -68.5% | -81.39% |
| Total Debt | $11.25M | $11.17M | $8.47M | $8.49M | -34.88% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
